AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today
AVITA Medical (NASDAQ: RCEL) is hosting its virtual Acute Wound Care Showcase 2025 on May 13, 2025, at 11:00 a.m. Pacific Time. The event will feature presentations from leading burn and trauma clinicians using AVITA's technologies, alongside patient testimonials about their treatment experiences with the company's solutions.
CEO Jim Corbett and SVP of Scientific and Medical Affairs Dr. Katie Bush will present AVITA's integrated approach to acute wound care, highlighting key technologies including RECELL®, Cohealyx™, and PermeaDerm®. The showcase will include a live Q&A session, with registration available through the company's website. A replay will be accessible from May 14 on AVITA Medical's Investor Relations site.
AVITA Medical (NASDAQ: RCEL) organizza il suo Showcase virtuale Acute Wound Care 2025 il 13 maggio 2025 alle 11:00, ora del Pacifico. L'evento presenterà interventi di medici esperti in ustioni e traumi che utilizzano le tecnologie AVITA, insieme a testimonianze di pazienti sui loro trattamenti con le soluzioni dell'azienda.
Il CEO Jim Corbett e la SVP Scientific and Medical Affairs, la Dr.ssa Katie Bush, illustreranno l'approccio integrato di AVITA alla cura delle ferite acute, mettendo in evidenza le tecnologie chiave come RECELL®, Cohealyx™ e PermeaDerm®. Lo showcase includerà una sessione di domande e risposte dal vivo, con registrazione disponibile sul sito web dell'azienda. Una replica sarà accessibile dal 14 maggio sul sito Investor Relations di AVITA Medical.
AVITA Medical (NASDAQ: RCEL) realizará su Showcase virtual Acute Wound Care 2025 el 13 de mayo de 2025 a las 11:00 a.m., hora del Pacífico. El evento contará con presentaciones de destacados médicos especialistas en quemaduras y traumatismos que utilizan las tecnologías de AVITA, junto con testimonios de pacientes sobre sus experiencias de tratamiento con las soluciones de la empresa.
El CEO Jim Corbett y la SVP de Asuntos Científicos y Médicos, la Dra. Katie Bush, presentarán el enfoque integrado de AVITA para el cuidado de heridas agudas, destacando tecnologías clave como RECELL®, Cohealyx™ y PermeaDerm®. El showcase incluirá una sesión de preguntas y respuestas en vivo, con inscripción disponible a través del sitio web de la compañía. Una repetición estará disponible desde el 14 de mayo en el sitio de Relaciones con Inversionistas de AVITA Medical.
AVITA Medical (NASDAQ: RCEL)은 2025년 5월 13일 오전 11시(태평양 표준시)에 가상 Acute Wound Care Showcase 2025를 개최합니다. 이번 행사에서는 AVITA 기술을 사용하는 주요 화상 및 외상 임상의들의 발표와 회사 솔루션으로 치료받은 환자들의 경험담이 소개됩니다.
CEO Jim Corbett와 과학 및 의료 담당 수석 부사장 Dr. Katie Bush가 AVITA의 급성 상처 치료 통합 접근법을 설명하며, RECELL®, Cohealyx™, PermeaDerm® 등 주요 기술들을 강조할 예정입니다. 쇼케이스에는 실시간 질의응답 세션이 포함되며, 회사 웹사이트를 통해 등록할 수 있습니다. 재방송은 5월 14일부터 AVITA Medical 투자자 관계 사이트에서 이용 가능합니다.
AVITA Medical (NASDAQ : RCEL) organise son événement virtuel Acute Wound Care Showcase 2025 le 13 mai 2025 à 11h00, heure du Pacifique. Cet événement présentera des interventions de cliniciens spécialisés en brûlures et traumatismes utilisant les technologies d’AVITA, ainsi que des témoignages de patients sur leurs expériences de traitement avec les solutions de l’entreprise.
Le PDG Jim Corbett et la SVP des affaires scientifiques et médicales, le Dr Katie Bush, présenteront l’approche intégrée d’AVITA en matière de soins des plaies aiguës, en mettant en avant les technologies clés telles que RECELL®, Cohealyx™ et PermeaDerm®. Le showcase comprendra une session de questions-réponses en direct, avec inscription disponible via le site web de l’entreprise. Une rediffusion sera accessible à partir du 14 mai sur le site des relations investisseurs d’AVITA Medical.
AVITA Medical (NASDAQ: RCEL) veranstaltet am 13. Mai 2025 um 11:00 Uhr Pazifischer Zeit seine virtuelle Acute Wound Care Showcase 2025. Die Veranstaltung umfasst Präsentationen führender Verbrennungs- und Traumakliniker, die AVITAs Technologien einsetzen, sowie Patientenberichte über ihre Behandlungserfahrungen mit den Lösungen des Unternehmens.
CEO Jim Corbett und die SVP für Wissenschaft und Medizin, Dr. Katie Bush, stellen AVITAs integrierten Ansatz zur Akutwundversorgung vor und heben dabei Schlüsseltechnologien wie RECELL®, Cohealyx™ und PermeaDerm® hervor. Die Showcase beinhaltet eine Live-Fragerunde, die Anmeldung ist über die Website des Unternehmens möglich. Eine Wiederholung ist ab dem 14. Mai auf der Investor-Relations-Seite von AVITA Medical verfügbar.
- None.
- None.
See how innovation is transforming patient outcomes through real-world clinical insights and patient stories
VALENCIA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, is hosting its Acute Wound Care Showcase 2025 virtually today, May 13, 2025, at 11:00 a.m. Pacific Time.
Attendees will hear directly from leading burn and trauma clinicians using AVITA Medical’s technologies, as well as from patients who have personally benefited from treatment following traumatic injuries. The event will also feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs, who will provide an overview of AVITA Medical’s integrated approach to acute wound care and highlight key technologies, including RECELL®, Cohealyx™, and PermeaDerm®.
“This is an exciting opportunity for the investment community to hear directly from the people behind our mission — including the patients whose lives have been changed by it,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “The Showcase offers a deeper look at how our technologies are changing the standard of care for acute wounds and delivering meaningful clinical and economic value.”
The event will conclude with a live Q&A session. Attendees are encouraged to register in advance and submit questions either during registration or live throughout the event. To join the live webcast, please register via the event page:
https://landing.avitamedical.com/acute-wound-healing-showcase-2025. A replay will be available beginning May 14 on the AVITA Medical Investor Relations site at ir.avitamedical.com.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute both Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
Investor & Media Contact: Jessica Ekeberg Phone +1-661-904-9269 investor@avitamedical.com media@avitamedical.com
FAQ
When is AVITA Medical (RCEL) hosting its Acute Wound Care Showcase 2025?
What products will be highlighted at AVITA Medical's 2025 showcase?
Who are the key speakers at AVITA Medical's 2025 Acute Wound Care Showcase?
How can investors access AVITA Medical's 2025 showcase replay?
